信迪利单抗注射液致免疫相关性膀胱炎1例分析

doi:10.19803/j.1672-8629.20250124

摘要/Abstract

摘要： 目的分析免疫检查点抑制剂（ICIs）致免疫相关性膀胱炎病例,为临床用药提供参考。方法对1例信迪利单抗致免疫相关性膀胱炎病例进行探讨,并回顾既往文献,总结其临床特征和治疗建议。结果信迪利单抗与免疫相关性膀胱炎关联性为很可能。经及时治疗,患者症状缓解后出院。结论免疫相关性膀胱炎目前尚缺乏明确的诊断标准,属于罕见免疫相关不良反应（irAEs）,如有ICIs用药史,出现尿路刺激症状,且抗感染治疗无效,需及时考虑免疫相关性膀胱炎可能。

关键词: 信迪利单抗, 免疫检查点抑制剂, 免疫相关性膀胱炎, 免疫相关不良反应, 药品不良反应

Abstract: Objective To analyze one case of immune-related cystitis induced by immune checkpoint inhibitors (ICIs) and provide references for clinical medications. Methods One case of immune-related cystitis caused by sintilimab was discussed, and related literature was reviewed to summarize its clinical characteristics and treatments. Results The association between sintilimab and immune-related cystitis was close. After quick symptomatic treatment, the patient was discharged after the symptoms improved. Conclusion There are currently no definitive diagnostic criteria for immune-related cystitis, which is a rare immune-related adverse event (irAEs). Immune-related cystitis is likely if a patient has used ICIs, presents with urinary irritation symptoms, and shows no response to anti-infective treatment.

Key words: Sintilimab, ICIs, Immune-Related Cystitis, irAEs, Adverse Drug Reactions

中图分类号:

R979
R994.11

黄慧玲, 童方琴, 宋璐. 信迪利单抗注射液致免疫相关性膀胱炎1例分析[J]. 中国药物警戒, 2025, 22(12): 1437-1440.

HUANG Huiling, TONG Fangqin, SONG Lu. One Case of Immune-Related Cystitis Caused by Sintilimab Injection[J]. Chinese Journal of Pharmacovigilance, 2025, 22(12): 1437-1440.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20250124

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I12/1437

参考文献

[1] Chinese Society of Clinical Oncology (CSCO) Guideline Working Committee. Guidelines for Managing Toxicity Related to Immune Checkpoint Inhibitors(免疫检查点抑制剂相关的毒性管理指南)[M]. Beijing: People's Medical Publishing House, 2023.
[2] National Comprehensive Cancer Network (NCCN). Management of Immunotherapy-Related Toxicities, Version 2[S]. NCCN, 2024.
[3] OZAKI K, TAKAHASHI H, MURAKAMI Y, et al.A Case of Cystitis after Administration of Nivolumab[J]. International Cancer Conference Journal, 2017, 6(4): 164-166.
[4] TU LF, YE Y, TANG XP, et al.Case Report: a Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events[J]. Frontiers in Oncology, 2021, 11: 757069.
[5] POSTOW MA, SIDLOW R, HELLMANN MD.Immune-Related Adverse Events Associated with Immune Checkpoint Blockade[J]. The New England Journal of Medicine, 2018, 378(2): 158-168.
[6] WANG ZQ, ZHU LP, HUANG Y, et al.Successful Treatment of Immune-Related Cystitis by Chai-Ling-Tang (Sairei-To) in a Gastric Carcinoma Patient: Case Report and Literature Review[J]. Explore, 2023, 19(3): 458-462.
[7] UEKI Y, MATSUKI M, KUBO T, et al.Non-Bacterial Cystitis with Increased Expression of Programmed Death-Ligand 1 in the Urothelium: an Unusual Immune-Related Adverse Event During Treatment with Pembrolizumab for Lung Adenocarcinoma[J]. IJU Case Reports, 2020, 3(6): 266-269.
[8] OBAYASHI A, HAMADA-NISHIMOTO M, FUJIMOTO Y, et al.Non-Bacterial Cystitis with Increased Expression of Programmed Cell Death Ligand 1 in the Urothelium: an Unusual Immune-Related Adverse Event after Atezolizumab Administration for Metastatic Breast Cancer[J]. Cureus, 2022, 14(5): e25486.
[9] LI J, YU YF, QI XW, et al.Immune-Related Ureteritis and Cystitis Induced by Immune Checkpoint Inhibitors: Case Report and Literature Review[J]. Frontiers in Immunology, 2023, 13: 1051577.
[10] ZHANG LZ, SHAN CT, XU J, et al.Immune-Related Ureteritis/Cystitis Caused by Lung Adenocarcinoma Treated with Combination of Sintilimab and Bevacizumab: a Case Report and Literature Review[J]. Chinese Journal of Cancer Biotherapy(中国肿瘤生物治疗杂志), 2023, 30(6): 533-537.
[11] ZHANG Y, LI HD, GAO B, et al.Immune-Related Cystitis Caused by Sintilimab: a Case Report[J]. Journal of Modern Urology(现代泌尿外科杂志), 2023, 28(6): 552-553.
[12] WANG B, WANG Q, SUI XJ, et al.Immune-Related Cystitis and Bladder Tuberculosis Induced by Sintilimab[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2024, 26(10): 636-638.
[13] ZHAO LY, JI YL.Pharmaceutical Care on a Patient with Immune-Associated Cystitis Caused by Camrelizumab[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2022, 39(1): 107-111.
[14] ZHANG S, DING QB, ZHANG JL, et al.Two Cases of Immune-Related Cystitis Caused by Neoadjuvant Immunotherapy for Bladder Cancer[J]. Journal of Clinical Surgery(临床外科杂志), 2022, 30(3): 276-279.
[15] LI SS, ZHEN K, XU Y, et al.Immune Checkpoint Inhibitors Related Cystoureteritis: a Case Report and Literature Review[J]. Chinese Journal of Lung Cancer(中国肺癌杂志), 2023, 26(9): 709-716.
[16] LI YH, ZHANG Q, PENG Z, et al.Immune-Related Cystitis Associated with Immune Checkpoint Inhibitor: a Case Report and Review of Literature[J]. Journal of Multidisciplinary Cancer Mana-gement(Electronic Version)(肿瘤综合治疗电子杂志), 2021, 7(3): 42-46.
[17] HUSSEINI KE, LAFOESTE H, MANSUET-LUPO A, et al.A Case of Severe Interstitial Cystitis Associated with Pembrolizumab[J]. Current Problems in Cancer: Case Reports, 2021, 4: 100101.
[18] SCHNEIDER S, ALEZRA E, YACOUB M, et al.Aseptic Cystitis Induced by Nivolumab and Ipilimumab Combination for Metastatic Melanoma[J]. Melanoma Research, 2021, 31(5): 487-489.
[19] ZHU LP, WANG ZQ, STEBBING J, et al.Immunotherapy-Related Cystitis: Case Report and Review of the Literature[J]. OncoTargets and Therapy, 2021, 14: 4321-4328.
[20] YAJIMA S, NAKANISHI Y, MATSUMOTO S, et al.Improvement of Urinary Symptoms after Bladder Biopsy: a Case of Pathologically Proven Allergy-Related Cystitis During Administration of Nivolumab[J]. IJU Case Reports, 2021, 4(4): 213-215.
[21] HE X, TU RF, ZENG SL, et al.Non-Bacterial Cystitis Secondary to Pembrolizumab: a Case Report and Review of the Literature[J]. Current Problems in Cancer, 2022, 46(4): 100863.
[22] SHIMATANI K, YOSHIMOTO T, DOI Y, et al. Two Cases of Nonbacterial Cystitis Associated with Nivolumab, the Antiprogrammed-Death-Receptor-1 Inhibitor[J]. Urology Case Reports, 2018, 17: 97-99.
[23] FUKUNAGA H, SUMII K, KAWAMURA S, et al.A Case of Steroid-Resistant Cystitis as an Immune-Related Adverse Event during Treatment with Nivolumab for Lung Cancer, Which Was Successfully Treated with Infliximab[J]. IJU Case Reports, 2022, 5(6): 521-523.
[24] ALHUSARI L, ABDALLAH M, NWANWENE K, et al.Acute Non-Infectious Cystitis Secondary to Immune-Related Adverse Events in a Patient Receiving Pembrolizumab for Treatment of Non-Small Cell Lung Cancer: a Case Report[J]. Cureus, 2024, 16(3): e55666.
[25] ZHOU QH, QIN ZQ, YAN PY, et al.Immune-Related Adverse Events with Severe Pain and Ureteral Expansion as the Main Manifestations: a Case Report of Tislelizumab-Induced Ureteritis/Cystitis and Review of the Literature[J]. Frontiers in Immunology, 2023, 14: 1226993.
[26] FAN Y, ZHAO J, MI Y, et al.Recurrent Cystitis Associated with 2 Programmed Death 1 Inhibitors: a Rare Case Report and Literature Review[J]. Journal of Immunotherapy, 2023, 46(9): 341-345.
[27] ANRAKU T, HASHIDATE H, IMAI T, et al.Successful Treatment of Immune-Related Cystitis with Bladder Hydrodistension[J]. IJU Case Reports, 2023, 6(4): 211-215.
[28] ZHU SH, BIAN LJ, LV J, et al.a Case Report of Non-Bacterial Cystitis Caused by Immune Checkpoint Inhibitors[J]. Frontiers in Immunology, 2021, 12: 788629.
[29] ZHANG P, YIN CY, YANG M.Case Reports of Immune-Related Cystitis and the Antibody Combination Hypothesis[J]. Immunotherapy, 2024, 16(16-17): 1039-1047.
[30] JI JX, LAI CH, ZHANG XW, et al.Immune-Related Adverse Events with Renal Colic as the Main Manifestation: a Case Report of Sintilimab-
Induced Ureteritis/Cystitis Treated by Ureteral Stent and Review of the Literature[J]. Frontiers in Immunology, 2024, 15: 1501415.
[31] DI CX, YU T, NI L, et al.Non-Bacterial Cystitis Caused by Pembro-lizumab Therapy for Adenocarcinoma of the Lung: a Case Report[J]. Frontiers in Immunology, 2024, 15: 1423123.